Clementina López Medina
Clementina is a Rheumatologist at the Reina Sofia University Hospital (Spain), a post-doctoral researcher at the Maimonides Institute of Biomedical Research of Cordoba (IMIBIC) and a Tenure Professor at the University of Cordoba (Spain). Her research focuses on the epidemiology and therapeutics of Spondyloarthritis and Psoriatic Arthritis. She also collaborates with translational researchers to identify potential diagnostic and predictive biomarkers in SpA. Clementina is a member of the EMEUNET Social Media sub-committee, member of the Spanish Group for the Study of Spondyloarthritis (GRESSER), Full ASAS member and GRAPPA member.
| Poster 0585 | Saturday, 16th November 2024 10:30 Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I Presenting author: Ogdie, A (USA) Title: Cycling to TNFi vs. switching to IL-17Ai after a first TNFi discontinuation among patients with PsA and axSpA: the CorEvitas PsA/SpA registry  This study includes patients with a diagnosis of PsA or axSpA enrolled in the CorEvitas PsA/SpA Registry who initiated a second TNFi or IL-17Ai after discontinuation of a first TNFi. The results suggest that switching from a TNFi to an IL-17Ai results in similar or numerically improved outcomes compared to cycling to a subsequent TNFi in both PsA and axSpA cohort. |
| Poster 1464 | Sunday, 17th November 2024 10:30 Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II Presenting author: Gossec, L (France) Title: Guselkumab and IL-17 inhibitors show comparable treatment persistence and effectiveness in psoriatic arthritis: 6-month interim results of the PsABIOnd observational cohort study PsABIOnd is an international, prospective observational cohort study in PsA patients starting Guselkumab (GUS) or IL-17i as first- to fourth— line of biologic therapy. By 6 months of treatment, PsA patients had similar persistence on treatment with GUS or IL-17i, and comparable rates of effectiveness across various PsA domains. |
| Poster 1468 | Sunday, 17th November 2024 10:30 Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II Presenting author: Benavent, D (Spain) Title: Efficacy of bDMARDs in early versus established disease in axial spondyloarthritis: a meta-analysis of randomized trials. This meta-analysis of all placebo-randomised controlled trials in patients with axSpA aims of investigating the influence of symptoms duration on treatment response. This analysis concludes that no significant difference has been found in the effect of bDMARDs vs placebo in early compared to established axSpA, defined according to several thresholds of symptom duration (between 2 and 5 years). |
| Oral 1756 | Sunday, 17th November 2024 15:15 Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA Presenting author: Heber, J (Denmark) Title: What is the impact of prior TNF inhibitor treatment on the time to achieve low disease activity and the durability of low disease activity? Real-world results based on 17858 European patients with axial spondyloarthritis initiating a TNF inhibitor or a IL17A inhibitor This European real-world cohort of patients with axSpA demonstrated that the time to achieve low disease activity (LDA) increased with the number of prior TNFi in both TNFi and IL-17Ai treatments. While the duration of LDA was shorter for TNFi-experienced than bio-naïve patients initiating IL-17Ai, prior TNFi did not affect durability in patients initiating TNFi. |
| Poster 2584 | Monday, 18th November 2024 13:45 Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II Presenting author: Mease, P (USA) Title: Zasocitinib (TAK-279), an oral, selective tyrosine kinase 2 inhibitor: achievement of remission and additional improvements in disease activity in patients with psoriatic arthritis enrolled in a Phase 2b trial. Zasocitinib (TAK-279) is an oral, selective TYK2 inhibitor under investigation for the treatment of PsA. In this phase 2b trial in patients with active PsA, treatment with Zasocitinib 15 and 30 mg resulted in higher rates of remission or LDA after 12 weeks in patients with PsA compared with placebo. |